A designed self-microemulsifying delivery system: Stability and Anti-inflammation in vivo enhancement of dihydromyricetin

[Display omitted] •Solubility and stability efficacy of dihydromyricetin (DYM) were improved by SMEDDS.•SMEDDS significantly increased the in vitro release of DYM.•SMEDDS showed superiority in delivering DYM.•DYM-SMEDDS exhibited superior anti-inflammatory and hepatoprotective effects. To enhance the stability and anti-inflammatory efficacy of dihydromyricetin (DYM), suitable excipients were selected for the development of a self-microemulsifying drug delivery system (SMEDDS). The formulated SMEDDS exhibited remarkable drug loading (117.47 ± 4.5 mg/g) and encapsulation rates (93.98 ± 3.6 %). Transmission electron microscope (TEM) revealed the nanoscale and spherical morphology of DYM-SMEDDS. Stability assessments demonstrated that DYM-SMEDDS maintained a consistent uniform small particle size after various cycles of exposure. In vitro release curve exhibited that DYM-SMEDDS released 91.27 ± 1.44 % of DYM within 24 h, surpassing the suspension by 2-fold. Furthermore, in vivo studies indicated that DYM-SMEDDS significantly inhibited the levels of pro-inflammatory factors, while promoting the activity of antioxidant enzymes (p